Featured Article Ranolazine Reduces Hemoglobin A1c in Diabetic Patients This finding from the MERLIN-TIMI 36 study was presented by Dr. David Morrow at the American Heart Association Scientific Sessions 2007. In MERLIN-TIMI 36, investigators randomized diabetic and non-diabetic patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) to intravenous ranolazine followed by 1,000 mg bid oral administration or placebo More Click here for more articles
Sponsor dave.md dave.md is a 501 (c)(3) not-for-profit organization. We are actively seeking sponsors to help keep this site going. For more information, contact us.
Hyperglycemia Lectures Part IV: Clinical Trials of ACS
In Part IV of a series of expert lectures on hyperglycemia in the acute care setting, Dr. Nicholas Emanuele, Director of Endocrinology at the Loyola University Chicago School of Medicine, discusses the major clinical trials on hyperglycemia in the setting of acute coronary syndromes, specifically with respect to the effect of intensive insulin therapy to achieve tight glycemic control on mortality in critically ill patients. The discussion begins with an overview of early prospective trials of intensive insulin therapy, including DIGAMI and the Leuven SICU study, to contemporary cohorts such as DIGAMI 2, CREATE-ECLA, and HI-5.
ADA 2008: Final Results from the ADVANCE Trial
June 9, 2008 - The first of three trials evaluating the efficacy of intensive glucose reduction in type 2 diabetic patients was presented at the American Diabetes Association Scientific Sessions 2008 More Info
ACC 2008: Results from the PERISCOPE Trial
April 1, 2008 - Pioglitazone (Actos, Takeda) prevents progression of atherosclerosis and reduces cardiovascular risk factors compared to glimepiride (Amaryl, sanofi-aventis) More Info
In Part IV of a series of expert lectures on hyperglycemia in the acute care setting, Dr. Nicholas Emanuele, Director of Endocrinology at the Loyola University Chicago School of Medicine, discusses the major clinical trials on hyperglycemia in the setting of acute coronary syndromes, specifically with respect to the effect of intensive insulin therapy to achieve tight glycemic control on mortality in critically ill patients. The discussion begins with an overview of early prospective trials of intensive insulin therapy, including DIGAMI and the Leuven SICU study, to contemporary cohorts such as DIGAMI 2, CREATE-ECLA, and HI-5.
